Search results for "drug resistance"

showing 10 items of 953 documents

The role of positive selection in hepatitis C virus

2008

Hepatitis C virus (HCV) is a major health problem worldwide, infecting an estimated 170 million people. In this study, we have employed a large data set of sequences (14,654 sequences from between 25 and 100 clone sequences per analyzed region and per patient) from 67 patients infected with HCV genotype 1 (23 subtype 1a and 44 subtype 1b). For all patients, a sample prior to combined therapy with alpha interferon plus ribavirin was available, whereas for some patients additional samples after 6 or 12 months of treatment were also available. Twenty-seven patients responded to treatment (12 subtype 1a and 15 subtype 1b) and forty patients did not respond to treatment (11 subtype 1a vs. 29 sub…

Microbiology (medical)Hepatitis C virusAlpha interferonHepacivirusViral Nonstructural ProteinsBiologymedicine.disease_causeMicrobiologyCohort Studieschemistry.chemical_compoundViral Envelope ProteinsSequence Analysis ProteinInterferonDrug Resistance ViralRibavirinGeneticsmedicineHumansAmino Acid SequenceSelection GeneticNS5AMolecular BiologyEcology Evolution Behavior and SystematicsChi-Square DistributionRibavirinInterferon-alphaHepatitis Cmedicine.diseaseComplementarity Determining RegionsHepatitis CVirologyHypervariable regionInfectious DiseaseschemistryImmunologyViral hepatitismedicine.drugInfection, Genetics and Evolution
researchProduct

Overcoming drug resistance in HSV, CMV, HBV and HCV infection.

2015

Although vaccination has provided as a very efficient preventive tool, antiviral therapy is still needed to control viral infections not avoidable by prophylaxis with vaccines; those caused by viruses for which a vaccine is available, but vaccination is not universally implemented or does not result in complete, long-term protection; and in immunocompromised individuals with reduced immune control of viral replication. After more than 50 years of the first licensing for an antiherpetic drug, novel compounds for herpes-simplex viruses and human cytomegalovirus will open new strategies for better control and management of these two recurrent viral infections. Besides, the development and use…

Microbiology (medical)Human cytomegalovirusHepatitis B virusvirusesHepacivirusCytomegalovirusDrug resistanceHepacivirusmedicine.disease_causeMicrobiologyAntiviral AgentsDrug DiscoveryDrug Resistance ViralmedicineHumansSimplexvirusHepatitis B virusbiologybusiness.industryHepatitis Bmedicine.diseasebiology.organism_classificationVirologyVaccinationViral replicationImmunologybusinessViral loadFuture microbiology
researchProduct

Chronic hepatitis B: who to treat and which choice of treatment?

2009

The goal of antiviral therapy in patients with chronic hepatitis B is to prevent, through persistent suppression of HBV replication, cirrhosis and hepatocellular carcinoma. Currently, seven drugs are available: IFN-alpha, pegylated interferon, lamivudine, adefovir dipivoxil, entecavir, telbivudine and tenofovir. The choice of the drugs should always take into consideration the clinical features of patients, the antiviral efficacy of each drug, the risk of developing resistance, the long-term safety profile, the method of administration and the cost of therapy. Ideal candidates for treatment are hepatitis B e antigen-positive patients with a prolonged phase of immune clearance and hepatitis …

Microbiology (medical)Liver Cirrhosismedicine.medical_specialtyHepatitis B virusCarcinoma Hepatocellularmedicine.disease_causeVirus ReplicationMicrobiologyGastroenterologyAntiviral AgentsDrug Administration ScheduleHepatitis B ChronicPegylated interferonVirologyTelbivudineInternal medicineDrug Resistance ViralmedicineAdefovirHumansRandomized Controlled Trials as TopicHepatitis B virusbusiness.industryNucleotidesLamivudineNucleosidesEntecavirHepatitis Bmedicine.diseaseVirologyInfectious DiseasesPractice Guidelines as TopicHepatitia BbusinessViral hepatitisantiviral Therapymedicine.drugExpert review of anti-infective therapy
researchProduct

Drug Resistance in Salmonella enterica ser. Typhimurium Bloodstream Infection, Malawi

2014

To the Editor: Salmonella enterica serotype Typhimurium is one of the most common causes of bloodstream infection in sub-Saharan Africa (1). Among adults, the principal risk factor for invasive nontyphoidal Salmonella (iNTS) disease is advanced HIV infection; up to 44% of HIV-infected patients experience bacteremic recurrence through recrudescence of the original infection (2,3). Epidemics of iNTS disease in sub-Saharan Africa have been associated with a novel genotype of S. enterica ser. Typhimurium of multilocus sequence type (ST) 313 that is rarely seen outside the region and is associated with multidrug resistance (MDR) to chloramphenicol, cotrimoxazole, and ampicillin (4,5). As a conse…

Microbiology (medical)MalawiLetterEpidemiologyDrug Resistance in Salmonella enterica ser. Typhimurium Bloodstream Infection Malawiwh_120lcsh:MedicineVirulenceDrug resistancewc_269fluoroquine resistancelcsh:Infectious and parasitic diseasesMicrobiologyqw_45PlasmidAntibiotic resistanceSalmonellalcsh:RC109-216antimicrobial resistanceLetters to the Editorbacteriawb_330biologyAccession number (library science)lcsh:RSalmonella entericaHIVbiology.organism_classificationVirologyEnterobacteriaceaeR13. Good healthMultiple drug resistanceInfectious DiseasesESBLSalmonella entericaAfricaserotype TyphimuriumHuman medicineKeywords: Salmonella
researchProduct

In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii

2005

To compare the activity of linezolid with a range of drugs used in the treatment of Mycobacterium kansasii infections.The percentages of resistant isolates against isoniazid, rifampicin and ethambutol were 2.9%, 1.9% and 2.9%, respectively. All isolates were susceptible to clarithromycin and moxifloxacin both with MIC(90) values of 0.125 mg/L. Linezolid was active against all isolates with MIC(50) and MIC(90) values of 0.5 and 1 mg/L, respectively, both below the susceptibility breakpoint established for mycobacteria.Linezolid, clarithromycin or moxifloxacin, could be used as alternative drugs for treatment of infections due to rifampicin-resistant isolates as well as short-course or interm…

Microbiology (medical)MoxifloxacinMicrobial Sensitivity TestsBiologyMicrobiologychemistry.chemical_compoundMoxifloxacinClarithromycinClarithromycinAcetamidesDrug Resistance Bacterialpolycyclic compoundsmedicineHumansheterocyclic compoundsPharmacology (medical)OxazolidinonesEthambutolAntibacterial agentPharmacologyMycobacterium kansasiiAza CompoundsIsoniazidLinezolidbiochemical phenomena metabolism and nutritionbacterial infections and mycosesbiology.organism_classificationAnti-Bacterial AgentsInfectious DiseaseschemistryMycobacterium kansasiiLinezolidQuinolinesbacteriaRifampicinFluoroquinolonesmedicine.drugJournal of Antimicrobial Chemotherapy
researchProduct

Outbreak of colonizations by extended-spectrum β-lactamase-producing Escherichia coli sequence type 131 in a neonatal intensive care unit, Italy

2013

Abstract Background Extended spectrum β-lactamases (ESBLs) often associated with resistance to aminoglycosides and fluoroquinolones have recently emerged in community-associated Escherichia coli. The worldwide clonal dissemination of E. coli sequence type (ST)131 is playing a prominent role. We describe an outbreak of colonizations by ESBL-producing E. coli (ESBL-E. coli) in the neonatal intensive care unit (NICU) of the University Hospital, Palermo, Italy. Methods An epidemiological investigation was conducted with the support of molecular typing. All children admitted to the NICU and colonized by ESBL-E. coli between January and June 2012, were included in the study. Cases were defined as…

Microbiology (medical)NICUmedicine.medical_specialtyNeonatal intensive care unitST131business.industryTransmission (medicine)EpidemiologyResearchPublic Health Environmental and Occupational HealthOutbreakDrug resistancemedicine.disease_causeMicrobiologyInfectious DiseasesMedical microbiologyEpidemiologymedicineInfection controlmulti-drug resistance E.coli ESBLPharmacology (medical)ESBL-Escherichia colibusinessEscherichia coliAntimicrobial Resistance and Infection Control
researchProduct

Reduction of nevirapine-driven HIV mutations by carbamazepine is modulated by CYP3A activity

2014

Item does not contain fulltext OBJECTIVES: The reduction in mother-to-child transmission of HIV-1 by single-dose nevirapine given at birth onset is achieved at the expense of de novo HIV-1 resistance mutations. In the VITA1 study, single-dose carbamazepine accelerated nevirapine elimination, but the accompanying trend towards fewer de novo HIV-1 mutations was statistically non-significant. METHODS: We investigated if the effect of carbamazepine was confounded by the individual variability in nevirapine metabolism and transport. RESULTS: Nine of 34 (26%) single-dose nevirapine-treated women had one or more nevirapine-associated resistance mutations, compared with 3 of 34 (9%) in the single-d…

Microbiology (medical)NevirapineCYP3AAnti-HIV AgentsHuman immunodeficiency virus (HIV)Mutation MissenseEndogenyHIV InfectionsPharmacologyBiologymedicine.disease_causeChemopreventionPregnancyDrug Resistance ViralmedicineClinical endpointCytochrome P-450 CYP3AHumansPharmacology (medical)NevirapinePharmacologyMutationCYP3A4Cytochrome P-450 CYP3A InducersCarbamazepinelnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]Infectious DiseasesCarbamazepineTreatment OutcomeHIV-1Femalemedicine.drug
researchProduct

Comparison of disc diffusion assay with the CLSI reference method (M27-A2) for testing in vitro posaconazole activity against common and uncommon yea…

2007

Objectives To evaluate the suitability of disc diffusion (DD) assay for testing posaconazole activity and to corroborate its activity against recently isolated yeasts by the CLSI reference microdilution M27-A2 method. Methods A total of 224 yeast isolates (7 species with 52 to 11 isolates each, and 15 species with 1 to 6 isolates) were evaluated, 125 were recent bloodstream isolates, 30 isolates from other sources and six ATCC isolates that included amphotericin B-resistant Candida albicans ATCC 200955, Candida lusitaniae (ATCC 200950, 200951, 200952 and 200953) and amphotericin B- and itraconazole-resistant Candida tropicalis ATCC 200956. MICs were determined at 24 and 48 h by following th…

Microbiology (medical)PosaconazoleAntifungal AgentsItraconazoleCoefficient of variationMicrobial Sensitivity TestsDrug resistanceBiologyMicrobiologyCandida tropicalisDrug Resistance FungalAmphotericin BmedicineHumansPharmacology (medical)Candida albicansCandidaPharmacologyCandida lusitaniaeCandidiasisReproducibility of ResultsReference StandardsTriazolesbiology.organism_classificationInfectious Diseasesmedicine.drugJournal of Antimicrobial Chemotherapy
researchProduct

Multidrug and broad-spectrum cephalosporin resistance among Salmonella enterica serotype enteritidis clinical isolates in southern Italy.

2002

ABSTRACT From 1992 to 1997, only six sporadic isolates of Salmonella enterica serotype Enteritidis from patients with cases of gastroenteritis in southern Italy exhibited resistance to broad-spectrum cephalosporins. Five isolates produced SHV-12, and one isolate encoded a class C β-lactamase. The bla SHV-12 gene was located in at least two different self-transferable plasmids, one of which also carried a novel class 1 integron.

Microbiology (medical)Serotypemedicine.drug_classEpidemiologySalmonella enteritidisCephalosporinIntegronbeta-LactamasesMicrobiologyPlasmidDrug Resistance Multiple BacterialGenotypemedicineHumansamoxicillin plus clavulanic acid; ampicillin; antibiotic agent; aztreonam; beta lactamase; cefotaxime; cefoxitin; ceftazidime; cephalosporin derivative; chloramphenicol; kanamycin; plasmid DNA; streptomycin; sulfonamide; tobramycin antibiotic resistance; article; bacterial infection; bacterium isolate; DNA probe; gastroenteritis; gastrointestinal infection; Italy; nonhuman; nucleotide sequence; phenotype; plasmid; priority journal; Salmonella; Salmonella enterica Base Sequence; beta-Lactamases; Cephalosporin Resistance; Cross Infection; Drug Resistance Multiple Bacterial; Gastroenteritis; Genes Bacterial; Humans; Italy; Plasmids; Salmonella enteritidis; Salmonella Infections Bacteria (microorganisms); Negibacteria; Salmonella; Salmonella entericaCephalosporin ResistanceCross InfectionbiologyBase SequenceCephalosporin Resistancebiochemical phenomena metabolism and nutritionbacterial infections and mycosesbiology.organism_classificationVirologyGastroenteritisItalySalmonella enteritidisSalmonella entericaGenes BacterialSalmonella Infectionsbiology.proteinPlasmidsJournal of clinical microbiology
researchProduct

Multiclonal emergence of carbapenem-resistant Klebsiella pneumoniae in Tuscany, Italy

2010

Microbiology (medical)Settore MED/07 - Microbiologia E Microbiologia ClinicaImipenemGenotypemedicine.drug_classCarbapenem resistant Klebsiella pneumoniaemedicine.medical_treatmentAntibioticsMicrobial Sensitivity TestsBiologySettore MED/42 - Igiene Generale E ApplicataMeropenembeta-Lactam Resistancebeta-LactamasesMicrobiologychemistry.chemical_compoundmedicineHumansPharmacology (medical)Molecular EpidemiologyKlebsiella pneumoniae resistenza ai carbapenemi multiclonaleGeneral MedicineDNA FingerprintingAnti-Bacterial AgentsBacterial Typing TechniquesElectrophoresis Gel Pulsed-FieldKlebsiella InfectionsMultiple drug resistanceKlebsiella pneumoniaePhenotypeInfectious DiseasesCarbapenemsItalychemistryBeta-lactamaseErtapenemmedicine.drugBeta lactam antibioticsInternational Journal of Antimicrobial Agents
researchProduct